The clinical epidemiology of sickle cell anemia In Africa
Sickle cell anemia (SCA) is the commonest severe monogenic disorders of humans. The disease has been highly characterized in high-income countries but not in sub-Saharan Africa where SCA is most prevalent. We conducted a retrospective cohort study of all children 0-13 years admitted from within a de...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 出版: |
Wiley
2017
|
| _version_ | 1826304614287278080 |
|---|---|
| author | Macharia, AW Mochamah, G Uyoga, S Ndila, CM Nyutu, G Makale, J Tendwa, M Nyatichi, E Ojal, J Shebe, M Awuondo, KO Mturi, N Peshu, N Tsofa, B Scott, JAG Maitland, K Williams, TN |
| author_facet | Macharia, AW Mochamah, G Uyoga, S Ndila, CM Nyutu, G Makale, J Tendwa, M Nyatichi, E Ojal, J Shebe, M Awuondo, KO Mturi, N Peshu, N Tsofa, B Scott, JAG Maitland, K Williams, TN |
| author_sort | Macharia, AW |
| collection | OXFORD |
| description | Sickle cell anemia (SCA) is the commonest severe monogenic disorders of humans. The disease has been highly characterized in high-income countries but not in sub-Saharan Africa where SCA is most prevalent. We conducted a retrospective cohort study of all children 0-13 years admitted from within a defined study area to Kilifi County Hospital in Kenya over a five-year period. Children were genotyped for SCA retrospectively and incidence rates calculated with reference to population data. Overall, 576 of 18,873 (3.1%) admissions had SCA of whom the majority (399; 69.3%) were previously undiagnosed. The incidence of all-cause hospital admission was 57.2/100 person years of observation (PYO; 95%CI 52.6-62.1) in children with SCA and 3.7/100 PYO (95%CI 3.7-3.8) in those without SCA (IRR 15.3; 95%CI 14.1-16.6). Rates were higher for the majority of syndromic diagnoses at all ages beyond the neonatal period, being especially high for severe anemia (hemoglobin < 50 g/L; IRR 58.8; 95%CI 50.3-68.7), stroke (IRR 486; 95%CI 68.4-3,450), bacteremia (IRR 23.4; 95%CI 17.4-31.4), and for bone (IRR 607; 95%CI 284-1,300), and joint (IRR 80.9; 95%CI 18.1-362) infections. The use of an algorithm based on just five clinical features would have identified approximately half of all SCA cases among hospital-admitted children with a number needed to test to identify each affected patient of only fourteen. Our study illustrates the clinical epidemiology of SCA in a malaria-endemic environment without specific interventions. The targeted testing of hospital-admitted children using the Kilifi Algorithm provides a pragmatic approach to early diagnosis in high-prevalence countries where newborn screening is unavailable. |
| first_indexed | 2024-03-07T06:20:30Z |
| format | Journal article |
| id | oxford-uuid:f28d0074-f722-48e0-a63c-a49f2ae452aa |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:20:30Z |
| publishDate | 2017 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:f28d0074-f722-48e0-a63c-a49f2ae452aa2022-03-27T12:04:44ZThe clinical epidemiology of sickle cell anemia In AfricaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f28d0074-f722-48e0-a63c-a49f2ae452aaSymplectic Elements at OxfordWiley2017Macharia, AWMochamah, GUyoga, SNdila, CMNyutu, GMakale, JTendwa, MNyatichi, EOjal, JShebe, MAwuondo, KOMturi, NPeshu, NTsofa, BScott, JAGMaitland, KWilliams, TNSickle cell anemia (SCA) is the commonest severe monogenic disorders of humans. The disease has been highly characterized in high-income countries but not in sub-Saharan Africa where SCA is most prevalent. We conducted a retrospective cohort study of all children 0-13 years admitted from within a defined study area to Kilifi County Hospital in Kenya over a five-year period. Children were genotyped for SCA retrospectively and incidence rates calculated with reference to population data. Overall, 576 of 18,873 (3.1%) admissions had SCA of whom the majority (399; 69.3%) were previously undiagnosed. The incidence of all-cause hospital admission was 57.2/100 person years of observation (PYO; 95%CI 52.6-62.1) in children with SCA and 3.7/100 PYO (95%CI 3.7-3.8) in those without SCA (IRR 15.3; 95%CI 14.1-16.6). Rates were higher for the majority of syndromic diagnoses at all ages beyond the neonatal period, being especially high for severe anemia (hemoglobin < 50 g/L; IRR 58.8; 95%CI 50.3-68.7), stroke (IRR 486; 95%CI 68.4-3,450), bacteremia (IRR 23.4; 95%CI 17.4-31.4), and for bone (IRR 607; 95%CI 284-1,300), and joint (IRR 80.9; 95%CI 18.1-362) infections. The use of an algorithm based on just five clinical features would have identified approximately half of all SCA cases among hospital-admitted children with a number needed to test to identify each affected patient of only fourteen. Our study illustrates the clinical epidemiology of SCA in a malaria-endemic environment without specific interventions. The targeted testing of hospital-admitted children using the Kilifi Algorithm provides a pragmatic approach to early diagnosis in high-prevalence countries where newborn screening is unavailable. |
| spellingShingle | Macharia, AW Mochamah, G Uyoga, S Ndila, CM Nyutu, G Makale, J Tendwa, M Nyatichi, E Ojal, J Shebe, M Awuondo, KO Mturi, N Peshu, N Tsofa, B Scott, JAG Maitland, K Williams, TN The clinical epidemiology of sickle cell anemia In Africa |
| title | The clinical epidemiology of sickle cell anemia In Africa |
| title_full | The clinical epidemiology of sickle cell anemia In Africa |
| title_fullStr | The clinical epidemiology of sickle cell anemia In Africa |
| title_full_unstemmed | The clinical epidemiology of sickle cell anemia In Africa |
| title_short | The clinical epidemiology of sickle cell anemia In Africa |
| title_sort | clinical epidemiology of sickle cell anemia in africa |
| work_keys_str_mv | AT machariaaw theclinicalepidemiologyofsicklecellanemiainafrica AT mochamahg theclinicalepidemiologyofsicklecellanemiainafrica AT uyogas theclinicalepidemiologyofsicklecellanemiainafrica AT ndilacm theclinicalepidemiologyofsicklecellanemiainafrica AT nyutug theclinicalepidemiologyofsicklecellanemiainafrica AT makalej theclinicalepidemiologyofsicklecellanemiainafrica AT tendwam theclinicalepidemiologyofsicklecellanemiainafrica AT nyatichie theclinicalepidemiologyofsicklecellanemiainafrica AT ojalj theclinicalepidemiologyofsicklecellanemiainafrica AT shebem theclinicalepidemiologyofsicklecellanemiainafrica AT awuondoko theclinicalepidemiologyofsicklecellanemiainafrica AT mturin theclinicalepidemiologyofsicklecellanemiainafrica AT peshun theclinicalepidemiologyofsicklecellanemiainafrica AT tsofab theclinicalepidemiologyofsicklecellanemiainafrica AT scottjag theclinicalepidemiologyofsicklecellanemiainafrica AT maitlandk theclinicalepidemiologyofsicklecellanemiainafrica AT williamstn theclinicalepidemiologyofsicklecellanemiainafrica AT machariaaw clinicalepidemiologyofsicklecellanemiainafrica AT mochamahg clinicalepidemiologyofsicklecellanemiainafrica AT uyogas clinicalepidemiologyofsicklecellanemiainafrica AT ndilacm clinicalepidemiologyofsicklecellanemiainafrica AT nyutug clinicalepidemiologyofsicklecellanemiainafrica AT makalej clinicalepidemiologyofsicklecellanemiainafrica AT tendwam clinicalepidemiologyofsicklecellanemiainafrica AT nyatichie clinicalepidemiologyofsicklecellanemiainafrica AT ojalj clinicalepidemiologyofsicklecellanemiainafrica AT shebem clinicalepidemiologyofsicklecellanemiainafrica AT awuondoko clinicalepidemiologyofsicklecellanemiainafrica AT mturin clinicalepidemiologyofsicklecellanemiainafrica AT peshun clinicalepidemiologyofsicklecellanemiainafrica AT tsofab clinicalepidemiologyofsicklecellanemiainafrica AT scottjag clinicalepidemiologyofsicklecellanemiainafrica AT maitlandk clinicalepidemiologyofsicklecellanemiainafrica AT williamstn clinicalepidemiologyofsicklecellanemiainafrica |